Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 19Vincristine 14Methotrexate 13blinatumomab 12Prednisone 12Cytarabine 12merphos 11Specimen Handling 10Mercaptopurine 10prednylidene 9pegaspargase 9deltacortene 9azathiopurine 9N,N-dicyclohexyl-isoborneol-10-sulfonamide 9Dexamethasone 9Leucovorin 8Doxorubicin 8Biopsy 8dexamethasone acetate 7dexamethasone 21-phosphate 7auricularum 7Etoposide 7Calcium Dobesilate 7Thioguanine 6Spinal Puncture 6Daunorubicin 6Asparaginase 6venetoclax 5fludarabine 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × ofatumumab × 30 days × Clear all
NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡